Caspofungin: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
|||
| Line 31: | Line 31: | ||
* No specific recommendations |
* No specific recommendations |
||
=== Obesity Dosing === |
|||
* 70 mg IV q24h |
|||
== Safety == |
== Safety == |
||
| Line 36: | Line 40: | ||
=== Adverse Drug Events === |
=== Adverse Drug Events === |
||
* Generally very safe with few adverse effects |
|||
| ⚫ | |||
* Most common adverse effects are infusion reaction with rash, pruritus, warmth |
|||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
* Reversible thrombocytopenia |
|||
=== Monitoring === |
=== Monitoring === |
||
* |
* Consider liver enzymes |
||
* No specific recommendations |
* No specific recommendations |
||
Latest revision as of 18:44, 5 February 2026
Background
- Echinocandin antifungal
Mechanism of Action
- Like all echinocandins, inhibits β-D-glucan synthase
Spectrum of Activity
- Active against Candida, Aspergillus
Pharmacokinetics and Pharmacodynamics
- Only 2% excreted unchanged in the kidney
Dosing
- Caspofungin 70 mg IV over 1 hour followed by 50 mg IV daily
- May be increased to 70 mg daily with cytochrome P450 3A4 inducers such as rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone, and phenytoin
Pediatric Dosing
- Casponfungin 70 mg/m2 IV followed by 50 mg/m2 IV daily
Hepatic Dosing
- Reduce to 70 mg IV load followed by 35 mg IV daily in cases of moderate or severe hepatic impairment (Child-Pugh class B or C)
Renal Dosing
- No specific recommendations
Obesity Dosing
- 70 mg IV q24h
Safety
Adverse Drug Events
- Generally very safe with few adverse effects
- Most common adverse effects are infusion reaction with rash, pruritus, warmth
- Sometimes fevers, chills, nausea, vomiting, rash, abdominal pain, headache, and diarrhea
- Occasional modest liver enzyme elevations
- Reversible thrombocytopenia
Monitoring
- Consider liver enzymes
- No specific recommendations